BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27259921)

  • 1. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.
    Burns SS; Chang LS
    Methods Mol Biol; 2016; 1427():59-72. PubMed ID: 27259921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
    Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
    PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
    Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
    Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
    Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.
    Mérel P; Hoang-Xuan K; Sanson M; Moreau-Aubry A; Bijlsma EK; Lazaro C; Moisan JP; Resche F; Nishisho I; Estivill X
    Genes Chromosomes Cancer; 1995 Jul; 13(3):211-6. PubMed ID: 7669741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
    Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
    Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.
    Pathmanaban ON; Sadler KV; Kamaly-Asl ID; King AT; Rutherford SA; Hammerbeck-Ward C; McCabe MG; Kilday JP; Beetz C; Poplawski NK; Evans DG; Smith MJ
    JAMA Neurol; 2017 Sep; 74(9):1123-1129. PubMed ID: 28759666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.
    Peyre M; Stemmer-Rachamimov A; Clermont-Taranchon E; Quentin S; El-Taraya N; Walczak C; Volk A; Niwa-Kawakita M; Karboul N; Giovannini M; Kalamarides M
    Oncogene; 2013 Sep; 32(36):4264-72. PubMed ID: 23045274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
    Waldt N; Scharnetzki D; Kesseler C; Kirches E; Stroscher N; Böhmer FD; Mawrin C
    J Neurol Sci; 2020 Jan; 408():116553. PubMed ID: 31715329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurofibromatosis type 2 gene is inactivated in schwannomas.
    Twist EC; Ruttledge MH; Rousseau M; Sanson M; Papi L; Merel P; Delattre O; Thomas G; Rouleau GA
    Hum Mol Genet; 1994 Jan; 3(1):147-51. PubMed ID: 8162016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.
    Bassiri K; Ferluga S; Sharma V; Syed N; Adams CL; Lasonder E; Hanemann CO
    EBioMedicine; 2017 Feb; 16():76-86. PubMed ID: 28126595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
    Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS
    Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients.
    Abi Jaoude S; Peyre M; Degos V; Goutagny S; Parfait B; Kalamarides M
    J Neurosurg; 2020 May; 134(5):1377-1385. PubMed ID: 32442973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
    Bhattacharyya S; Oblinger JL; Beauchamp RL; Yin Z; Erdin S; Koundinya P; Ware AD; Ferrer M; Jordan JT; Plotkin SR; Xu L; Chang LS; Ramesh V
    Neuro Oncol; 2023 Sep; 25(9):1617-1630. PubMed ID: 36806881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models of meningiomas.
    Mawrin C
    Chin Clin Oncol; 2017 Jul; 6(Suppl 1):S6. PubMed ID: 28595424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.
    Spear SA; Burns SS; Oblinger JL; Ren Y; Pan L; Kinghorn AD; Welling DB; Chang LS
    Otol Neurotol; 2013 Oct; 34(8):1519-27. PubMed ID: 23928514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inherited genetic syndromes and meningiomas.
    Look A; Lonser RR
    Handb Clin Neurol; 2020; 169():121-129. PubMed ID: 32553283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.